OBJECTIVE: Since 2007, the use of erythropoiesis-stimulating agents (ESAs) to treat anemia in cancer patients receiving chemotherapy has been increasingly restricted in the USA. This study assessed hemoglobin (Hb) decline over time among chemotherapy patients. METHODS: Episodes of chemotherapy care were identified in a large US-oncology electronic medical record database; weekly Hb levels were computed in the first 8 weeks. Unadjusted and adjusted proportions of patient-weeks with Hb decline > 1 g/dl (i.e. representing clinically significant decline) within 1 or 2 weeks were analyzed. RESULTS: Between 2006 and 2009, unadjusted proportions of patient-weeks with Hb decline > 1 g/dl increased (1-week, from 12.7% to 14.9%; 2-week, from 19.3% to 26.3%). Adjusted 1-week proportions in 2007 were similar to 2006, but increased in 2008 (odds ratio [OR] 1.135; 95% confidence intervals [CI] 1.067, 1.208) and in 2009 (OR 1.235; 95% CI 1.094, 1.395) . Adjusted 2-week proportions had the same pattern. CONCLUSIONS: Since restrictions on ESA use were introduced in the USA, more patients have experienced a clinically significant Hb decline after chemotherapy initiation. Initiating anemia therapy at the earliest indicated opportunity may help reduce the risk of such declines.
Introduction
Anemia, which is a deficiency in the concentration of hemoglobin (Hb)-containing red blood cells, commonly occurs among cancer patients receiving chemotherapy. 1, 2 Anemia presents direct and indirect costs, both to cancer patients and to society. Anemic patients may experience reduced quality of life and increased morbidity. Specifically, they may present JW Hill, Z Cong, G Hess et al.
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with a range of symptoms, most frequently fatigue but also dizziness, shortness of breath, palpitations, lack of endurance, and angina. 3 -8 Anemia (and associated fatigue) due to concomitantly administered chemotherapy also places substantial burdens on patients, healthcare providers, payers, caregivers, and employers. These burdens include increased medical-resource utilization and costs, as well as nonmedical costs such as transportation, lost productivity, and absence from work. 7,9 -12 Treatment options for chemotherapyinduced anemia are red blood cell (RBC) transfusions and/or erythropoiesisstimulating agents (ESAs). 13 -16 RBC transfusions are most often used to raise Hb levels rapidly in patients with Hb < 8 g/dl. 17, 18 This Hb-raising effect does not persist, however, and patients are likely to require additional anemia treatment over the long term. 19 -23 The transient effect of RBC transfusions can be costly and resource intensive, with increased physician visits and lengthy transfusion times placing undue burden on patients and caregivers. 24 ESAs bind to the same receptor and trigger the same physiologic response as endogenous erythropoietin 25 and are, therefore, considered reasonable long-term alternatives to RBC transfusions. ESAs have been shown to improve Hb concentrations and reduce the need for transfusions in patients with chemotherapy induced anemia, 25 -28 but clinical trial data suggest that ESA use increases the risk of thromboembolic events, and/or may promote tumor progression or shorten survival for some patients. 29 -31 Since 2007, the use of ESAs in patients with chemotherapy induced anemia has been increasingly restricted on product labels and in reimbursement and practice guidelines, in the USA. In 2007, a National Coverage Decision (NCD) of the Center for Medicare and Medicaid Services evaluated coverage for the use of ESAs in nonrenal disease. The results of this NCD were to cease reimbursement of ESAs for treatment of anemia of cancer 18 that was unrelated to cancer treatment, and tied reimbursement to meeting specific requirements for Hb levels. 32 Payment for ESA therapy was denied in cases with pretreatment Hb ≥ 10 g/dl, where Hb was > 10 g/dl after 4 weeks of therapy, or if Hb levels increased by > 1 g/dl in a 2-week period of therapy, since Hb responses meeting these thresholds indicated there was no need to continue such therapy. Reimbursements were restricted to a maximum duration of ESA therapy of up to 8 weeks following completion of a chemotherapy regimen. The National Comprehensive Cancer Network (NCCN) announced similar guidelines relating to the use of ESAs in cancer and treatment-related anemia in December 2007. 13 Then, in August 2008, the Food and Drug Administration limited initiation of ESAs to cases with Hb < 10 g/dl, constrained maintenance administrations to the lowest ESA dose required to avoid transfusions, and identified ESAs as not indicated for chemotherapy treatment with an anticipated outcome of cure, among other changes. 33 Little is known about the association between the restriction of ESA use and Hb decline after initiation of chemotherapy in clinical practice in the USA. The present study used retrospective electronic medical records (EMR) data, collected from registered oncology patients, to investigate the impact of changes in ESA guidelines on clinically significant Hb decline in patients with cancer after chemotherapy initiation. In addition, the associations between patient characteristics and clinically significant Hb decline were analyzed, to identify the patient subgroups that require careful anemia management.
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Patients and methods
STUDY DESIGN
This retrospective, US-based, observational study included episodes of chemotherapy care (EOCCs) between 1 January 2006 and 30 April 2009. EOCCs were identified from an oncology EMR database of approximately 250 000 cancer patients receiving care from 111 practice sites across 25 US States.
The start of an EOCC was defined as the date of a chemotherapy administration (index date) in the EMR, with a preceding period of ≥ 90 days with no evidence of chemotherapy use. The end of an EOCC was the date of a chemotherapy administration (end date) that was followed by a period of ≥ 90 days without chemotherapy use. Only EOCCs that began (and were completed) within the study period were included in the analysis. EOCCs of patients aged ≥ 18 years, with Hb measurements in the week before EOCC initiation, and in ≥ 2 consecutive weeks of the 8 weeks after the EOCC initiation date, were eligible for analysis.
The mean Hb level was calculated in weekly intervals at baseline (defined as the 7-day period up to and including the year EOCCs began) and in each of the following weeks where data were recorded in the EMR. Changes in Hb levels in the first 8 weeks of EOCCs were analyzed. If ESA therapy was initiated within the 8-week period, or if EOCCs ended within 8 weeks, Hb levels only up to the start of ESA therapy or end of EOCCs were included in the analyses. In addition, if the mean Hb level dropped to below the common threshold for RBC transfusion (8.5 g/dl) before week 8, EOCCs were followed until the week before this threshold was met. NCCN guidelines (2009) 34 14, 34 recommend that cancer patients with Hb < 9 g/dl should be evaluated for transfusion, although an individualized approach may be needed. 14 
DEFINITION OF OUTCOME VARIABLES
A clinically significant change in Hb level is generally considered to be between 0.66 and 1 g/dl. 35 The present study used two outcome variables to identify clinically significant declines in Hb after the onset of chemotherapy: (i) a drop in mean Hb of > 1 g/dl compared with the previous week; (ii) a drop in mean Hb of > 1 g/dl compared with the level 2 weeks previously. For the first outcome variable, observational data from each EOCC for each week in which Hb was measured were analyzed to determine the change for that week. Similarly, for the second outcome measure, the EOCCs contributed data for each week in which computation of change over a 2-week period was possible.
STATISTICAL ANALYSES
The proportions of patient-weeks with a ≥ 1 g/dl (i.e. clinically significant) decline in Hb over a 1-or 2-week period after EOCC initiation were summarized by: (i) calendar year of EOCC initiation (2006, 2007, 2008, 2009 ); (ii) patient age (< 65 years, ≥ 65 years); (iii) gender (male, female); (iv) Hb level in the week before and including the EOCC initiation date (< 9, 9 -10, 10 -11, 11 -12, ≥ 12 g/dl); (v) US region (Midwest, Northeast, South, West); (vi) cancer type (breast, colorectal, hematologic, lung, other); (vii) platinum chemotherapy treatment (yes, no); (viii) taxane chemotherapy treatment (yes, no). Pearson's χ 2 -test was used to assess homogeneity of the proportions among JW Hill, Z Cong, G Hess et al. Hemoglobin decline in chemotherapy patients patient subgroups. A Z-test was used to compare differences in proportions for EOCC with and without ESA use.
The probability that a patient would experience a clinically significant decline in Hb in a weekly period during the first 8 weeks of EOCCs was analyzed using multivariate logistic regression models with generalized estimating equations (GEE), including the patient and EOCC characteristics mentioned above. GEE incorporates information on the correlation between multiple observations made for the same patient. Since the probability of experiencing a clinically significant decrease in Hb in any given week after the start of EOCC is expected to correlate with the decline in Hb in previous weeks, an autoregressive correlation specification was chosen. The same analyses were conducted to estimate the probability of a clinically significant drop over a 2-week period. A Wald test was used to test the statistical significance of each coefficient in the model. A P-value ≤ 0.05 was considered to be statistically significant. Analyses were conducted using SAS ® statistical software (SAS Enterprise Guide, version 4.1), SAS Institute, Cary, NC, USA.
Results
A total of 71 571 weekly observations on Hb change were identified from 46 108 unique EOCCs completed during the study period; 23 046 weekly observations on Hb change were identified from the subset of EOCCs in which ESAs were administered. For the analyses of Hb change over a 2-week period, 66 640 and 20 377 biweekly observations on Hb change were identified from all EOCCs and the subset of EOCCs in which ESAs were administered, respectively.
Data regarding the proportion of patientweeks with a clinically significant decrease in Hb within 1 week are given in Table 1 . Excluding gender, all patient and EOCC characteristics listed below were significantly associated with a clinically significant Hb decline (P < 0.05, all comparisons): age < 65 years; Hb ≥ 12 g/dl at the time (year) when EOCC began; time (year) across the study period (i.e. higher rate of decline in later years compared with 2006); US geographical region (particularly the West); cancer type (particularly lung cancer); platinum or taxane chemotherapy. Use of ESA therapy also declined over time, from 45% of patients in 2006 to 20% in 2008 (P < 0.0001). Over the same period, mean Hb at initiation of ESA therapy declined from 10.7 to 9.7 g/dl, and mean time from chemotherapy initiation to ESA initiation increased from 44 to 66 days.
The proportion of patient-weeks with a clinically significant Hb decline within 1 week was higher in the sample of EOCCs with ESA use than in the full sample (P < 0.0001 for non-ESA versus ESA samples; Table 1 ). For EOCCs with ESAs, again all EOCCs and patient characteristics except gender were significantly associated with a clinically significant Hb decline within 1 week (P < 0.05, all comparisons). As seen with the full sample, the subsample of EOCCs with ESA use also showed a significant increase in the proportion of patients with a clinically significant decline in Hb over time (P = 0.0003).
Data regarding the proportion of patientweeks with a clinically significant decline in Hb within a 2-week time period are given in Table 2 . For all EOCCs, the proportion of patients with such a decline was higher over a 2-week period than over a 1-week period (20.3% vs 12.9%, Tables 1 and 2 ). All patient and EOCC characteristics except gender were significantly associated with a clinically significant Hb decline during a 2-week period (P < 0.05 for all comparisons; Table 2 ), JW Hill, Z Cong, G Hess et al. 
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being substantially higher for the following: patients aged < 65 years; Hb ≥ 12 g/dl at the time (year) when EOCC began; EOCCs initiated in 2009; patients with lung cancer; platinum or taxane chemotherapy. The proportion of EOCCs with a clinically significant decline in Hb within 2 weeks increased significantly over time (P < 0.05).
The proportion of patient-weeks with a clinically significant decline in Hb over 2 weeks was higher in patients who received ESAs than in the full sample (P < 0.0001 for non-ESA versus ESA samples; Table 2 ). In addition, the proportion of patients treated with ESAs who had a clinically significant decline in Hb over 2 weeks increased significantly over time (P < 0.05). All characteristics had significant associations with such a decline in Hb over 2 weeks (P < 0.05 for all comparisons; Table 2 ).
Results of the multivariate logistic GEE models are given in Tables 3 and 4 . The probability of a clinically significant decrease in Hb over 1 week increased over time for all EOCCs (Table 3 ). After controlling for patient and EOCC characteristics, a similar probability was observed for EOCCs initiated in 2006 or 2007, but this probability increased in 2008, and then increased further in the first quarter of 2009. Other predictors of a clinically significant 1-week decline in Hb were: higher Hb level at EOCC initiation; West, Midwest, and South US region (compared with Northeast); breast, lung, hematologic, and other cancer types (compared with colorectal cancer); use of platinum chemotherapy; and not using taxane chemotherapy.
Episodes of chemotherapy care with ESA use experienced a greater upward trend in the proportion of Hb decline (prior to anemia therapy) over time, compared with the results from all EOCCs (Table 3) . Compared with 2006, the probability of clinically significant 1-week decline in Hb increased in 2007, again in 2008 and increased further in the first quarter of 2009. Other predictors were: higher Hb at the start of EOCC; Midwest region (compared with Northeast); breast, lung, hematologic, and other cancer types (compared with colorectal cancer); and not using taxane chemotherapy. Among patients treated with taxane chemotherapy, older patients (≥ 65 years) had a lower risk than younger patients.
Findings were similar between the 1-and 2-week results for all EOCCs, but the 2-week results indicated a slightly higher trend of increasing probability for a significant Hb decline over time (Table 4 ). Compared with EOCCs initiated in 2006, the 2-week probability of Hb decline was similar in 2007, but increased in 2008 and in the first quarter of 2009. Additional predictors were: higher Hb level at the start of chemotherapy; West, Midwest, and South US regions (compared with Northeast); breast, lung, hematologic, and other cancer types (compared with colorectal cancer); use of platinum chemotherapy; and not using taxane chemotherapy. EOCCs with ESAs experienced a greater upward trend in the probability of a clinically significant decrease in Hb over 2 weeks (before ESA initiation) compared with all EOCCs combined ( Table 4) . Compared with 2006, the probability increased in 2007, again in 2008, and increased further in the first quarter of 2009. Other significant predictors were mostly identical to those of all EOCCs.
Discussion
The present study suggests that patients on chemotherapy are at greater risk of a clinically significant decline in Hb in the years immediately after the implementation of restrictions on ESA use compared with the year before implementation. In the most JW Hill, Z Cong, G Hess et al. decreased and mean time from chemotherapy initiation to ESA initiation increased. The downward trend in ESA use after 2007 may also reflect, in part, a shift in the perceived appropriateness of treating anemia to target a 'normal' Hb level, rather than using the minimum treatment required to avoid a transfusion. The revised guidelines favor the latter approach, and restrict the target population to patients with more severe anemia and those receiving myelosuppressive chemotherapy with no anticipation of cure. Finally, possible overprescription of ESAs prior to policy changes that started in 2007 may have contributed to the subsequent downward As expected, the increase in the probability of a clinically significant decline in Hb was highest in the subset of patients who were subsequently administered ESAs. This likely reflects the clinical difference between the patient groups, such that patients receiving ESAs were more likely to be more severely anemic and require therapy and, therefore, were more likely to have had a clinically significant Hb decline prior to initiation of anemia treatment, compared with other patients.
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Several characteristics were associated with a decline in Hb levels, including breast or lung cancer (compared with colorectal cancer). Patients with higher baseline Hb levels were more likely to experience significant Hb decline than those with lower baseline levels. While this seems counterintuitive, it may reflect the study design, which censored data at initiation of ESA therapy or when Hb fell below 8.5 g/dl (the threshold at which RBC transfusion is likely). Patients with lower baseline Hb levels may be more likely to experience clinically significant declines (and pass the threshold for ESA therapy or transfusion) and are more likely, therefore, to leave the sample. This may have resulted in data from patients with lower baseline Hb values having a lower risk of clinically significant decline; the higher risk of such decline in patients with higher baseline Hb suggests that these patients should be monitored regularly to determine whether therapeutic intervention is appropriate. Patients receiving platinumbased chemotherapy had a 1.3 to 1.4-fold increased risk of a decline in Hb level compared with those not receiving such chemotherapy.
In contrast, patients receiving taxane-based chemotherapy had a slightly lower risk of a decline in Hb compared with those not receiving such chemotherapy. Data regarding cancer stage were incomplete in this database, and the intensity of chemotherapy varies substantially by cancer stage. Caution should, therefore, be used when interpreting the association between chemotherapy types and Hb trends.
The significant decline in Hb levels between 2008 and 2009, compared with 2006, may be associated with the changes in ESA use implemented in 2007. Physicians should monitor Hb regularly after the initiation of chemotherapy in order to determine the earliest indicated opportunity to begin treatment to minimize the risk of anemia. The association between certain cancer types and Hb decline indicates a need for closer surveillance for these patients throughout the chemotherapy episode.
There were several limitations to the present study. First, data regarding RBC transfusions were not reported in the EMRs by some cancer-care providers included in the study, and a threshold Hb level of 8.5 g/dl was, therefore, used to determine when the patient was a likely candidate for transfusion: patients may have received a RBC transfusion before or after this threshold, or may not have received a transfusion at all. Second, Hb data were not always measured at each time period for each patient over the 8-week period examined, resulting in missing data for some time intervals: Hb values in the EMR database represent tests ordered and evaluated by physicians, and analyses of repeated measures (GEE estimates) appropriately accounted for these missing observations. Finally, the key outcome of the study (i.e. the risk of a decline in Hb > 1 g/dl over a 1-or 2-week period), may or may not translate into the risk of an adverse event for JW Hill, Z Cong, G Hess et al.
the patient. This study measured only how declines in Hb after initiation of chemotherapy changed following policy changes on ESA therapy use. Other outcomes of interest that may be considered in future research include the changes in risks, such as thromboembolism, which may have declined after implementation of the policy changes restricting ESA use.
In conclusion, the present study suggests that chemotherapy patients experienced a greater risk of a clinically significant decline in Hb after policy changes to restrict ESA use were implemented, compared with before such policy changes took place. Initiation of anemia therapy at the earliest indicated opportunity may help maintain Hb levels and reduce the risk of any clinically significant decline.
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